Skip to content
Open access

Bile Cell Block-Derived DNA for Next-Generation Sequencing in Cholangiocarcinoma: A Comparison With Surgical Specimens.

Nov 2026 · Journal of hepato-biliary-pancreatic sciences · 0 citations · 12 references
Medicine

TL;DR

As bile CB is easy to prepare in general hospitals, bile cell-based NGS may help address the difficulty of obtaining surgical NGS samples for cholangiocarcinoma.

Abstract

Objectives

A sufficient amount of cancer tissue for next-generation sequencing (NGS) is difficult to obtain from patients with unresectable cholangiocarcinoma. We evaluated whether bile cell block (CB) samples provide a DNA source of sufficient quantity and quality for NGS compared with surgical specimens.

Methods

NGS results of paired bile CB and surgical specimens from 14 patients were compared.

Results

Median number of malignant cells on one glass slide of CB specimen was 50. Although median DNA concentration and amount of extracted DNA were significantly lower in the CB than those in the surgical specimens, NGS success rate did not differ significantly (CB, 64%; surgical specimen, 86%). In a pair-wise comparison of eight patients with successful NGS of both bile CB and surgical specimens, median gene matching rate was 99%, and median coverage rate of surgical genes based on CB genes was 100%. The presence of ≥ 30 malignant cells on a single slide was identified as a practical indicator of successful NGS of CB using receiver operating characteristic curve, and this threshold increased the NGS success rate to 80%.

Conclusions

As bile CB is easy to prepare in general hospitals, bile cell-based NGS may help address the difficulty of obtaining surgical NGS samples for cholangiocarcinoma.

Read PDF

Similar papers

Open access Sep 2026

Analytical Performance of Routine Next-Generation Sequencing in Biopsy and Resection Specimens from Patients with Colorectal Adenocarcinoma: A Two-Center Study

Despite lower tumor cellularity and DNA concentration, appropriately selected biopsy specimens yielded high rates of evaluable sequencing and Tier I–II variant detection in this cohort, with no statistically significant differences in sequencing quality metrics or Tier I–II variant yield between specimen types.

Erdem Çomut, Ömer Atmış · 0 citations
Open access Nov 2026

Plasma cell-free DNA-based next-generation sequencing for molecular profiling of diffuse gliomas

Abstract Purpose To evaluate the utility of plasma-derived cell-free DNA (cfDNA) using targeted next-generation sequencing (NGS) for molecular profiling of diffuse gliomas (DG) by assessing concordance with matched tumor tissue DNA, mutation profiles, variant allele frequencies, therapeutically actionable alterations,...

Swati Singh, Jyotsna Singh, S. Bhardwaj et al. · 0 citations
Open access Oct 2026

Assessment of a direct fluorescence-based cell-free DNA assay for evaluating the extent of metastatic dissemination: An exploratory study.

Fluorescence-based cell-free DNA (cfDNA) assays quantify nucleic acids without the need for DNA extraction and amplification. The present study investigated whether cfDNA levels differed between patients with active cancer and those with no evidence of disease (NED). Blood samples from patients with metastatic cancer (...

Jae-Joon Kim, Yangjeong Lee, Yun Jeong Hong et al. · 0 citations
Review Open access Oct 2026

Bile Cell-Free DNA as a Liquid Biopsy for Biliary Tract Malignancies: A Scoping Review

Simple Summary Cancers of the bile ducts and gallbladder are usually discovered late, when treatment options are limited. Doctors normally look for these cancers by brushing cells from the narrowed duct during an endoscopic procedure, but this approach misses more than half of them. Blood tests that search for tumor ge...

A. Dhir, Brian Martins, Z. Yeung et al. · 0 citations
Open access Sep 2026

Optimizing DNA Extraction from Archival Prostate Biopsy Samples.

PURPOSE In this paper, we compare the performance of three distinct nucleic acid extraction protocols in a large population-based prostate cancer cohort, aiming to optimize DNA yield from limited tumor samples in prostate needle biopsies. MATERIAL AND METHODS We utilized two commercially available extraction kits and...

A. Amaral, Lia DePaula Oliveira, O. Dairo et al. · 0 citations
Open access Nov 2026

Utilization of Circulating Tumor DNA Testing in Biliary Tract Cancers

Background: Circulating tumor DNA is a promising biomarker for molecular residual disease and recurrence surveillance in biliary tract cancers. We evaluated the association between postoperative tumor-informed ctDNA and recurrence-free survival (RFS) and assessed the performance of initial and longitudinal ctDNA survei...

M. Sheu, N. Naleid, O. Pawar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.